Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Royalty Pharma plc RPRX

• Dividend Yield: 3.05%
• Citigroup analyst Andrew Baum maintained a Buy rating and cut the price target from $60 to $40 on Oct. 25. This analyst has an accuracy rate of 72%.
• Morgan Stanley analyst Terence Flynn maintained an Overweight rating and raised the price target from $48 to $51 on July 11. This analyst has an accuracy rate of 69%.
• Recent News: On Nov. 4, Royalty Pharma and Syndax Pharmaceuticals entered into $350 million royalty funding agreement for Niktimvo.
• Benzinga Pro's real-time newsfeed alerted to latest RPRX news.

Johnson & Johnson JNJ

• Dividend Yield: 3.13%
• Citigroup analyst Joanne Wuensch maintained a Buy rating and raised the price target from $180 to $185 on Oct. 16. This analyst has an accuracy rate of 77%.
• Wells Fargo analyst Larry Biegelsen maintained an Equal-Weight rating and increased the price target from $163 to $166 on Oct. 16. This analyst has an accuracy rate of 72%.
• Recent News: On Oct. 28, Johnson & Johnson announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn's disease.
• Benzinga Pro's real-time newsfeed alerted to latest JNJ news.

Medtronic plc MDT

• Dividend Yield: 3.12%
• Truist Securities analyst Richard Newitter maintained a Hold rating and raised the price target from $90 to $93 on Oct. 14. This analyst has an accuracy rate of 74%.
• Citigroup analyst Joanne Wuensch maintained a Neutral rating and increased the price target from $85 to $92 on Oct. 1. This analyst has an accuracy rate of 77%.
• Recent News: Medtronic will report financial results for its second quarter of fiscal year 2025 on Tuesday, Nov. 19.
• Benzinga Pro’s charting tool helped identify the trend in MDT stock.

Read More: Jim Cramer Says He Can’t Recommend This Major Automaker, Ceva Is ‘Way Too High’